Decreased in-vitro cellular drug resistance by addition of vascular endothelial growth factor receptor (VEGFR) inhibitor, PTK787/ZK 222584, to conventional chemotherapy in pediatric AML.

被引：0
|
作者：
De Bont, ESJM [1 ]
Meeuwsen-de Boer, T [1 ]
Scherpen, F [1 ]
Streefland, E [1 ]
Kamps, WA [1 ]
机构：
[1] Univ Groningen Hosp, Groningen, Netherlands
来源：
LEUKEMIA | 2003年 / 17卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O40
引用
收藏
页码：668 / 668
页数：1
相关论文
共 32 条
  • [21] PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging
    Drevs, J
    Müller-Driver, R
    Wittig, C
    Fuxius, S
    Esser, N
    Hugenschmidt, H
    Konerding, MA
    Allegrini, PR
    Wood, J
    Hennig, J
    Unger, C
    Marme, D
    CANCER RESEARCH, 2002, 62 (14) : 4015 - 4022
  • [22] Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and flood flow in a murine renal cell carcinoma model
    Drevs, J
    Hofmann, I
    Hugenschmidt, H
    Wittig, C
    Madjar, H
    Müller, M
    Wood, J
    Martiny-Baron, G
    Unger, C
    Marmé, D
    CANCER RESEARCH, 2000, 60 (17) : 4819 - 4824
  • [23] Randomized, Placebo-Controlled, Phase III Study of First-Line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK 222584, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Metastatic Colorectal Adenocarcinoma
    Hecht, J. Randolph
    Trarbach, Tanja
    Hainsworth, John D.
    Major, Pierre
    Jager, Elke
    Wolff, Robert A.
    Lloyd-Salvant, Katherine
    Bodoky, Gyorgy
    Pendergrass, Kelly
    Berg, William
    Chen, Bee-Lian
    Jalava, Tarja
    Meinhardt, Gerold
    Laurent, Dirk
    Lebwohl, David
    Kerr, David
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15) : 1997 - 2003
  • [24] Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases
    Lee, L
    Sharma, S
    Morgan, B
    Allegrini, P
    Schnell, C
    Brueggen, J
    Cozens, R
    Horsfield, M
    Guenther, C
    Steward, WP
    Drevs, J
    Lebwohl, D
    Wood, J
    McSheehy, PMJ
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (06) : 761 - 771
  • [25] Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases
    Lucy Lee
    Sunil Sharma
    Bruno Morgan
    Peter Allegrini
    Christian Schnell
    Josef Brueggen
    Robert Cozens
    Mark Horsfield
    Clemens Guenther
    Will P. Steward
    Joachim Drevs
    David Lebwohl
    Jeanette Wood
    Paul M. J. McSheehy
    Cancer Chemotherapy and Pharmacology, 2006, 57 : 761 - 771
  • [26] Phase I trial of the mTOR inhibitor RAD001 (R) in combination with two schedules of the vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor PTK787/ZK 222584 (P) in patients (pts) with advanced solid tumors
    Dy, G. K.
    Croghan, G. A.
    Qi, Y.
    Glockner, J.
    Hanson, L.
    Roos, M.
    Tan, A. D.
    Molina, J. R.
    Adjei, A. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [27] Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma
    Brander, Danielle
    Rizzieri, David
    Gockerman, Jon
    Diehl, Louis
    Shea, Thomas Charles
    Decastro, Carlos
    Moore, Joseph O.
    Beaven, Anne
    LEUKEMIA & LYMPHOMA, 2013, 54 (12) : 2627 - 2630
  • [28] PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma turnours and inhibits their growth in vivo
    Rudin, M
    McSheehy, PMJ
    Allegrini, PR
    Rausch, M
    Baumann, D
    Becquet, M
    Brecht, K
    Brueggen, J
    Ferretti, S
    Schaeffer, F
    Schnell, C
    Wood, J
    NMR IN BIOMEDICINE, 2005, 18 (05) : 308 - 321
  • [29] Defining the biologically active dose for PTK787/ZK222584 (PTK/ZK), a vascular endothelial growth factor (VEGF) receptor inhibitor, based on the assessment of two biomarkers [dynamic contrast enhanced magnetic resonance imaging (DCE-MRI), plasma VEGF] in two phase I studies
    Morgan, B
    Drevs, J
    Steward, WP
    Lee, L
    DiLea, C
    Marme, D
    Mross, K
    Thomas, A
    Laurent, D
    Dugan, M
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S75 - S75
  • [30] A phase I trial of a combination of the mTOR Inhibitor Everolimus (RAD001) and two schedules of the vascular enclothelial growth factor (VEGF) receptor tyrosine kinase inhibitor Vatalanib (PTK787/ZK 222584) in patients (pts) with advanced solid tumors
    Dy, G.
    Croghan, G.
    Furth, A.
    Reid, J.
    Hanson, L.
    Roos, M.
    Tan, A.
    Adjei, A.
    EJC SUPPLEMENTS, 2006, 4 (12): : 15 - 15
1234